Table 1

Baseline characteristics of horizon scan reports by clinical domain

Diagnostic tests by clinical domainDate report
published		Studies in primary care (n)/all studies (N)Sample sizes of primary studies (range)Publication dates primary studies (range)Intended role of the testComponents missing
Cardiovascular 21/158
 The D-dimer test for ruling out DVT in primary care20092/91028–12951997–2009TI/IV/VI
 Point-of-care test for INR coagulometers201016/3218–8922000–2010R–
 Point-of-care test for cardiac troponin20110/1820–22632001–2011R–
 Point-of-care pulse wave analysis20110/722–7492008–2011RIII/IV/V/VI
 Point-of-care test for BNP20111/15150–6062001–2011TIV
 Handheld ECG monitors for the detection of atrial fibrillation in primary care20130/918–5051990–2012RI/IV/V
 Genotyping polymorphisms of warfarin metabolism20130/220–1122009–2010TIII/IV/V/VI
 Point-of-care test for hFABP20141/2152–10742003–2013AI/VI
 Portable ultrasound devices20141/243–9431993–2013TVI
 Point-of-care test for a panel of cardiac markers20140/2133–52011999–2012TI/III/V/VI
Digestive 12/81
 Point-of-care test for hepatitis C virus20110/6100–22061999–2011RIV/V/VI
 Point-of-care test for coeliac disease20121/987–26902004–2009TI/III/IV/V
 Transcutaneous bilirubin measurement20130/2831–8491996–2011TI/III/IV
 Point-of-care calprotectin tests20141/814–1402008–2012TI/III/IV/V/VI
 Point-of-care faecal occult blood testing201410/30100–851491990–2013T–
Endocrine/metabolic 28/76
 Point-of-care blood test for ketones in diabetes20096/933–5292000–2006T–
 Point-of-care test for the analysis of lipid panels20109/1334–49681995–2010R–
 Point-of-care test for HbA1c20106/723–78932003–2010RIV*
 Point-of-care test for thyroid-stimulating hormone20130/164–641999–1999RI/III/IV/V/VI
 Point-of-care HbA1c tests: diagnosis of diabetes20167/4623–62261996–2015RIII/IV*
Female genital 2/8
 Chlamydia trachomatis testing20092/8162–25171998–2009RII/V/VI
General and unspecified 7/34
 Point-of-care test for total white cell count20101/6120–5002000–2009RIII/IV/V/VI
 Point-of-care test for CRP20116/820–8981997–2011R–
 Point-of-care test for procalcitonin20120/854–3842001–2010AIV
 Non-contact infrared thermometers20130/690–8552005–2013AIII/V/VI
 Point-of-care test for malaria20150/698–981999–2014RI/V
Musculoskeletal 0/1
 Autoimmune markers for rheumatoid arthritis20120/1880–8802008–2008RI/III/IV/V/VI
Neurological 1/9
 Point-of-care test for handheld nerve conduction measurement devices for carpal tunnel syndrome20121/933–11902000–2011RIV/V
Pregnancy 2/11
 Urinalysis self-testing in pregnancy20142/949–4 44 2201991–2012AIV
 Point-of-care test for quantitative blood hCG20150/240–402014–2015TIII/IV/V/VI
Respiratory 25/84
 Pulse oximetry in primary care20091/4114–21271997–2004TI/III/IV/V
 A portable handheld electronic nose in the diagnosis of cancer, asthma and infection20095/830–6651999–2009TIII/IV/V/VI
 Point-of-care spirometry20114/1113–10411996–2009RV
 Point-of-care automated lung sound analysis20113/221–1001996–2010AIV/V
 Point-of-care tests for influenza in children20128/2973–91862002–2011RI/IV
 Point-of-care tests for group A streptococcus20154/10121–8922002–2015RI
Skin 1/7
 Dermoscopy for the diagnosis of melanoma in primary care20091/796–30532001–2008TI/IV/V
Urological 7/31
 Point-of-care urine albumin–creatinine ratio test20106/1183–49681999–2010R–
 Point-of-care test for creatinine20141/1020–4012007–2013RIV/V/VI
 Point-of-care NGAL tests20150/10100–12192007–2013AIII/IV/V
Grand total106/500

  • Evaluation components: I, analytical performance; II, clinical performance; III, clinical effectiveness; IV, comparative clinical effectiveness; V, cost-effectiveness; VI, broader impact.

  • *Same diagnostic technology.

  • A, add-on; BNP, B-natriuretic peptide; CRP, C reactive protein; DVT, deep vein thrombosis; HbA1c, glycated haemoglobin; hCG, human chorionic gonadotropin; hFABP, heart-type fatty acid-binding protein; INR, international normalised ratio; n, number; NGAL, neutrophil gelatinase-associated lipocalin; R, replacement; T, triage